ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SNG Synairgen Plc

5.13
0.00 (0.00%)
Last Updated: 08:00:22
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 5.13 4.50 5.99 1,180 08:00:22
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 0 -17.65M -0.0876 -0.59 10.33M

Synairgen plc Holding(s) in Company (6346S)

26/06/2018 1:05pm

UK Regulatory


Synairgen (LSE:SNG)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Synairgen Charts.

TIDMSNG

RNS Number : 6346S

Synairgen plc

26 June 2018

Synairgen plc

('Synairgen' or the 'Company')

Holding in Company

Southampton, UK: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that it was today informed that Leonard Licht, a private investor, now holds 7,700,000 ordinary shares of 1 pence each in the capital of the Company through his Choice Bespoke SIPP.

This represents 8.48% of the total voting rights of the Company.

For further enquiries, please contact:

Synairgen plc

Richard Marsden, Chief Executive Officer

John Ward, Finance Director

Tel: + 44 (0) 23 8051 2800

finnCap

Geoff Nash, Max Bullen-Smith (Corporate Finance)

Stephen Norcross, (Corporate Broking)

Tel: + 44 (0) 20 7220 0500

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott / Sukaina Virji / Laura Thornton

synairgen@consilium-comms.com

Tel: +44 (0) 20 3709 5701

About Synairgen

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Leveraging its scientific and clinical facilities at Southampton General Hospital, the Company uses in vitro and ex vivo models to progress opportunities into clinical development. The BioBank of human samples is used in these models to increase confidence in the likelihood of successful drug development.

Synairgen is currently running a two-part Phase II trial evaluating SNG001, the Company's wholly-owned inhaled interferon beta (IFN-beta) therapeutic candidate. The Phase II trial, called SG015, has been designed to assess the safety of SNG001 in COPD patients and its clinical benefit in these patients when they have a cold or flu infection, a major driver of COPD exacerbations.

Core to Synairgen's business strategy is the realisation of value via licensing transactions. In August 2015 the Company entered into a collaboration with Pharmaxis to develop an oral LOXL2 inhibitor to reduce fibrosis in patients with idiopathic pulmonary fibrosis (IPF). In December 2017 the collaboration agreement was amended as Pharmaxis took on full responsibility for the programme, with Synairgen receiving a GBP5 million upfront payment and circa 17% of any future partnering proceeds from all fibrotic indications.

Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

HOLLLFIFRVIRFIT

(END) Dow Jones Newswires

June 26, 2018 08:05 ET (12:05 GMT)

1 Year Synairgen Chart

1 Year Synairgen Chart

1 Month Synairgen Chart

1 Month Synairgen Chart

Your Recent History

Delayed Upgrade Clock